Sorafenib-Daten auf dem Kongress 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO)

13. - 17. Mai 2005

Dienstag, 17. Mai:
Investoren-Telefonkonferenz ASCO Review 2005

Die Audio-Aufzeichnung dieser Veranstaltung ist nicht mehr verfügbar.

Fact Sheets und Hintergrundinformationen
(nur in Englisch verfügbar)
Sorafenib Clinical Program OverviewDownload (PDF, 120 KB) sammeln
Sorafenib Fact SheetDownload (PDF, 139 KB) sammeln
Renal Cell Carcinoma Fact SheetDownload (PDF, 114 KB) sammeln
Hepatocellular Carcinoma Fact SheetDownload (PDF, 138 KB) sammeln
Melanoma Fact SheetDownload (PDF, 119 KB) sammeln
Sorafenib at ASCO 2005Download (PDF, 119 KB) sammeln

Abstracts und Präsentationen zu Sorafenib auf dem ASCO-Meeting 2005

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: LBA4510)

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: 4544 )

A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) ( Abstract No: 5566)

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients ( Abstract No: 7508)

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma ( Abstract No: 3037)

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) ( Abstract No: 3067)

Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma ( Abstract No: 3005)

Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: A prospective study ( Abstract No: 3069)

ASCO Homepage:

Informationen zu Klinischen Studien:

American Cancer Society:

Informationen zu Nierenkrebs:

Informationen zu Leberkrebs:

Informationen zu Hautkrebs:

Informationen zu Häufigkeit, Prävalenz und Mortalität von Krebs (GLOBOCAN):

Letzte Änderung: 13. Januar 2014 Copyright © Bayer AG